Invited Commentary: In a Genomic Era, Should We Promote Dopamine Homeostasis to Treat Opiate/ Opioid Abuse, Instead of Blocking Brain Dopamine Function?
| العنوان: | Invited Commentary: In a Genomic Era, Should We Promote Dopamine Homeostasis to Treat Opiate/ Opioid Abuse, Instead of Blocking Brain Dopamine Function? |
|---|---|
| المؤلفون: | Marcelo Febo, Kenneth Blum, Edward J Modestino, Bruce Steinberg, Thomas J. McLaughlin, B. William Downs, David Baron, Roger L. Waite, Mona Li, Rajendra D Badgaiyan, Eric R. Braverman, Lyle Fried |
| المصدر: | Medical Research Archives. 5 |
| بيانات النشر: | Knowledge Enterprise Journals, 2017. |
| سنة النشر: | 2017 |
| مصطلحات موضوعية: | medicine.medical_specialty, Framingham Risk Score, business.industry, media_common.quotation_subject, Addiction, Dopaminergic, Genomics, Abstinence, Bioinformatics, Dopamine agonist, Dopamine, Medicine, Opiate, business, Psychiatry, media_common, medicine.drug |
| الوصف: | We are currently in a genomics era with important implications for the field of psychiatry. An understanding of DNA, as well as polymorphic changes affecting the brain’s reward circuitry, has provided a new way of approaching and thinking about addictive behaviors. Our current goal is to provide a foundation for more accurate genetic diagnoses as well, as the application of dopamine agonist therapy (pro-dopamine regulation), in order to balance dopaminergic activation. Based upon our extensive research, we are proposing a novel approach which challenges the Addiction recovery field to utilize these tools by introducing them into inpatient/outpatient addiction treatment programs The following tools, we hope, will change the recovery landscape: The Genetic Addiction Risk Score (GARS™) for Reward Deficiency Syndrome (RDS) diagnoses; the Comprehensive Analysis Of Reported Drugs (CARD™) to establish compliance of prescribed medications and abstinence during treatment; natural Dopamine agonistic therapy (KB220™); mRNA (patent pending) to resolve pre-and post-candidate gene expressions in Reward Deficiency Syndrome (RDS). As a result we have dubbed, this paradigm shift as: “The Reward Deficiency Solutions System (RDSS™).”Wc 180Keywords: Genome, Genetic Addiction Risk Score (GARS), KB220 variants, Pro-Dopamine Regulation, Pain, Opiate/opioid epidemic |
| تدمد: | 2375-1924 2375-1916 |
| DOI: | 10.18103/mra.v5i2.995 |
| URL الوصول: | https://explore.openaire.eu/search/publication?articleId=doi_________::1af484571b8d07f21fcd5370afdd7ba6 https://doi.org/10.18103/mra.v5i2.995 |
| Rights: | OPEN |
| رقم الانضمام: | edsair.doi...........1af484571b8d07f21fcd5370afdd7ba6 |
| قاعدة البيانات: | OpenAIRE |
| تدمد: | 23751924 23751916 |
|---|---|
| DOI: | 10.18103/mra.v5i2.995 |